Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nephrogenic diabetes insipidus

D G Bichet1

  • 1Centre de recherche, Hôpital du Sacré-Coeur de Montréal and Department of Medicine, Université de Montréal, Québec, Canada.

The American Journal of Medicine
|November 27, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.

Molecular genetics and metabolism·2021
Same author

Vasopressin: physiology, assessment and osmosensation.

Journal of internal medicine·2017
Same author

Outcomes of patients treated through the Canadian Fabry disease initiative.

Molecular genetics and metabolism·2014
Same author

A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.

Molecular genetics and metabolism·2013
Same author

Inherited secondary nephrogenic diabetes insipidus: concentrating on humans.

American journal of physiology. Renal physiology·2013
Same author

Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases.

Nephron. Physiology·2010
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026
Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026
See all related articles

Nephrogenic diabetes insipidus (NDI) impairs kidney water reabsorption due to vasopressin receptor or aquaporin-2 gene mutations. Early diagnosis of congenital NDI is crucial to prevent dehydration and manage this rare genetic disorder.

Area of Science:

  • Nephrology
  • Genetics
  • Molecular Biology

Background:

  • Nephrogenic diabetes insipidus (NDI) is a condition where kidneys cannot concentrate urine, despite normal arginine vasopressin (AVP) levels.
  • Congenital NDI presents at birth with polyuria and polydipsia, requiring prompt recognition to prevent dehydration.
  • Most congenital NDI cases stem from mutations in the AVPR2 gene, encoding the vasopressin V2 receptor.

Purpose of the Study:

  • To elucidate the genetic basis and molecular mechanisms of congenital nephrogenic diabetes insipidus.
  • To differentiate between mutations affecting the vasopressin V2 receptor and aquaporin-2 water channel.
  • To highlight diagnostic advancements for NDI management.

Main Methods:

  • Genetic analysis of patients with congenital NDI.

Related Experiment Videos

  • In vitro studies of mutant AVPR2 and AQP2 proteins.
  • Characterization of receptor trafficking and signaling pathways.

    • Main Results:

    • Over 90% of congenital NDI cases involve AVPR2 gene mutations, leading to intracellular receptor trapping or impaired function.
    • Less than 10% of congenital NDI cases are linked to aquaporin-2 (AQP2) gene mutations, also causing intracellular protein retention.
    • Acquired NDI, distinct from congenital forms, is more common and associated with AQP2 downregulation.

    Conclusions:

    • Mutations in AVPR2 and AQP2 genes disrupt the kidney's response to vasopressin, causing NDI.
    • Understanding these molecular defects provides critical diagnostic insights for NDI patients.
    • Advances in NDI research offer practical "bedside physiology" tools for clinical care.